EF24 has potent anti-tumor activity in orally bioavailable squamous cell carcinoma (OSCC) via deactivation of the MAPK/ERK signaling pathway. EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK. Sequential treatments of EF24 and 12-phorbol-13-myristate acetate, a MAPK/ERK activator, result in a significant increase of activated MEK1 and ERK, and reversed cell viability. References: Lelli D, Pedone C, Sahebkar A. Curcumin and treatment of melanoma: The potential role of microRNAs. Biomed Pharmacother. 2017 Apr;88:832-834. doi: 10.1016/j.biopha.2017.01.078. Epub 2017 Feb 24. Review. PubMed PMID: 28167449.

纯度：≥98%

CAS：342808-40-6